| Item type |
学術雑誌論文 / Journal Article_02(1) |
| 公開日 |
2025-06-13 |
| タイトル |
|
|
タイトル |
A tumor metastasis-associated molecule TWIST1 is a favorable target for cancer immunotherapy due to its immunogenicity |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
cancer immunoediting |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
cancer immunotherapy |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
cancer vaccine |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
metastasis-associated molecules |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
shared |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
tumor antigens |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
vaccination therapy |
| 資源タイプ |
|
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 著者 |
Yuki, Yajima
Akemi, Kosaka
Kei, Ishibashi
Shunsuke, Yasuda
Hiroki, Komatsuda
Toshihiro, Nagato
Kensuke, Oikawa
Masahiro, Kitada
Masanori, Takekawa
Takumi, Kumai
Kenzo, Ohara
Takayuki, Ohkuri
Hiroya, Kobayashi
|
| bibliographic_information |
en : Cancer science
巻 113,
号 8,
p. 2526-2535,
発行日 2022-08-01
|
| ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
1347-9032 |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
1349-7006 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1111/cas.15429 |
| リンクURL |
|
|
内容記述タイプ |
Other |
|
内容記述 |
https://onlinelibrary.wiley.com/doi/10.1111/cas.15429 |
|
言語 |
en |
| item_1716186501932 |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
35579200 |
| item_5_description_33 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Although neoantigens are one of the most favorable targets in cancer immunotherapy, it is less versatile and costly to apply neoantigen-derived cancer vaccines to patients due to individual variation. It is, therefore, important to find highly immunogenic antigens between tumor-specific or associated antigens that are shared among patients. Considering the cancer immunoediting theory, immunogenic tumor cells cannot survive in the early phase of tumor progression including two processes: elimination and equilibrium. We hypothesized that highly immunogenic molecules are allowed to be expressed in tumor cells after an immune suppressive tumor microenvironment was established, if these molecules contribute to tumor survival. In the current study, we focused on TWIST1 as a candidate for highly immunogenic antigens because it is upregulated in tumor cells under hypoxia and promotes tumor metastasis, which is observed in the late phase of tumor progression. We demonstrated that TWIST1 had an immunogenic peptide sequence TWIST1140-162 , which effectively activated TWIST1-specific CD4+ T-cells. In a short-term culture system, we detected more TWIST1-specific responses in breast cancer patients compared with in healthy donors. Vaccination with the TWIST1 peptide also showed efficient expansion of TWIST1-reactive HTLs in humanized mice. These findings indicate that TWIST1 is a highly immunogenic shared antigen and a favorable target for cancer immunotherapy. |
|
言語 |
en |
| 注記 |
|
|
内容記述タイプ |
Other |
|
注記 |
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction
in any medium, provided the original work is properly cited and is not used for commercial purposes. |
|
言語 |
en |
| 出版タイプ |
|
|
出版タイプ |
VoR |
| item_5_textarea_42 |
|
|
|
en |
|
|
© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association |
35579200.pdf (1.1 MB)
.png)
